Retatrutide: The Triple Agonist GLP-1 Drug Outperforming Everything

Retatrutide is the most powerful weight-loss drug ever tested in a clinical trial. In Phase 2 studies, patients lost up to 24.2% of their body weight in 48 weeks. In the first Phase 3 trial, average weight loss reached 71.2 pounds. Those numbers put every existing GLP-1 medication — including semaglutide and tirzepatide — firmly in second place.

So what makes retatrutide different? The answer lies in a third receptor target that no approved medication has yet exploited: the glucagon receptor.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly. It is a triple hormone receptor agonist, meaning it simultaneously activates three distinct receptors in the body:

• GLP-1 receptor (glucagon-like peptide-1)
• GIP receptor (glucose-dependent insulinotropic polypeptide)
• Glucagon receptor (GCGR)

Tirzepatide (Mounjaro/Zepbound), the current best-in-class dual agonist, activates the first two. Retatrutide adds the glucagon receptor on top of that — and the metabolic consequences of that addition are substantial.

As of 2026, retatrutide is still investigational and not FDA-approved. Availability is not expected until 2027–2028 at the earliest, pending Phase 3 completion and regulatory review.

How Retatrutide Works: The Science of Triple Agonism

GLP-1 Receptor Activation

GLP-1 receptor agonism is the foundation shared by semaglutide, tirzepatide, and retatrutide. When the GLP-1 receptor fires, the brain receives satiety signals that reduce appetite and food intake. The stomach empties more slowly, blunting post-meal blood sugar spikes. Insulin secretion increases in a glucose-dependent manner, meaning it only kicks in when blood sugar is elevated — reducing hypoglycemia risk significantly.

GIP Receptor Activation

GIP (glucose-dependent insulinotropic polypeptide) amplifies the insulin response and plays a role in fat metabolism. Paradoxically, GIP receptor activation in the brain appears to enhance the appetite-suppressing effects of GLP-1, rather than counteracting it. This synergy is why tirzepatide outperforms semaglutide despite the counterintuitive pharmacology. Retatrutide carries this same dual synergy forward.

Glucagon Receptor Activation — The Critical Differentiator

Glucagon is traditionally known as the "counter-regulatory" hormone that raises blood sugar. So why would a metabolic drug activate it?

The answer is thermogenesis and hepatic fat clearance.

Glucagon receptor agonism drives several effects that GLP-1 and GIP alone cannot produce:

• Brown adipose tissue (BAT) activation: Glucagon receptors, when stimulated, activate the cAMP/PKA signaling pathway, which upregulates uncoupling protein-1 (UCP-1) in brown fat. UCP-1 dissipates energy as heat rather than storing it — effectively increasing resting metabolic rate.
• Hepatic fat oxidation: Glucagon promotes fatty acid oxidation in the liver, driving down hepatic fat content. This is the mechanism behind retatrutide's dramatic reductions in liver fat (up to 82% in clinical trials).
• Ketogenesis and amino acid catabolism: These metabolic shifts further enhance fat burning and energy expenditure.

Importantly, the GLP-1 component keeps blood sugar stable even while glucagon is active — because GLP-1's insulinotropic effect offsets any hyperglycemic signal from glucagon. The three receptors work in concert.

Clinical Trial Results

Phase 2 — Obesity (NEJM, 2023)

The landmark Phase 2 obesity trial published in the New England Journal of Medicine randomized participants to retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo once weekly for 48 weeks.

Results at 48 weeks:

• 1 mg dose: −8.7% body weight
• 4 mg dose: −17.1% body weight
• 8 mg dose: −22.8% body weight
• 12 mg dose: −24.2% body weight
• Placebo: −2.1% body weight

At 24 weeks, the 12 mg dose had already produced −17.5% weight loss, suggesting the trajectory continues well beyond the trial period.

Phase 2 — Type 2 Diabetes

In participants with type 2 diabetes, retatrutide achieved 16.9% mean weight loss after 36 weeks. HbA1c improved by 2.2 percentage points, and 82% of participants reached HbA1c ≤ 6.5% — a level considered near-normal glycemic control.

Phase 2 — Liver Disease (Nature Medicine, 2024)

A dedicated Phase 2a trial in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) showed retatrutide produced:

• −42.9% relative liver fat reduction at 1 mg
• −57.0% at 4 mg
• −81.4% at 8 mg
• −82.4% at 12 mg

These reductions represent a potential breakthrough for MASLD/MASH (formerly NAFLD/NASH), a condition with limited treatment options. The glucagon-driven hepatic fat oxidation mechanism appears to be a major driver here.

Phase 3 — TRIUMPH-4 (2025)

Eli Lilly announced results from the first successful Phase 3 trial (TRIUMPH-4) in December 2025. The trial evaluated retatrutide in adults with obesity or overweight and knee osteoarthritis, without diabetes.

Key finding: average weight loss of up to 71.2 pounds (approximately 32 kg), along with significant relief from osteoarthritis pain — a clinically meaningful secondary outcome that reflects both the metabolic and anti-inflammatory effects of weight reduction at this scale.

Retatrutide vs. Semaglutide vs. Tirzepatide

Head-to-head trials have not been completed, but cross-trial comparisons offer a rough hierarchy of efficacy:

The pattern is clear: each additional receptor target adds roughly 5–8 percentage points of weight loss. The addition of glucagon receptor agonism also differentiates retatrutide in liver disease and resting energy expenditure — effects semaglutide and tirzepatide do not replicate to the same degree.

That said, direct comparisons are complicated by different trial designs, patient populations, dose escalation protocols, and trial durations. Retatrutide's apparent superiority is compelling, but it should be understood as hypothesis-generating until head-to-head Phase 3 data exists.

Side Effects and Safety Profile

The side effect profile of retatrutide closely mirrors that of other GLP-1 class medications, with gastrointestinal effects dominating:

• Nausea: 38–43% of participants (dose-dependent)
• Diarrhea: 33–35%
• Vomiting: 20–21%
• Constipation: less common but reported

Most GI adverse events were mild to moderate in severity and occurred primarily during dose escalation phases. Discontinuation rates of 12–18% were observed in Phase 3 — somewhat higher than semaglutide's ~7%, which may reflect the more aggressive dose escalation or the higher peak doses used.

Like semaglutide and tirzepatide, retatrutide carries a theoretical concern for thyroid C-cell tumors (based on animal studies) and pancreatitis. Long-term human safety data are still being collected across ongoing Phase 3 trials.

The glucagon receptor component introduces a unique consideration: in people without working GLP-1/GIP co-agonism, standalone glucagon receptor activation could raise blood sugar. Retatrutide's design specifically counterbalances this through concurrent GLP-1 activity, but metabolic monitoring remains important in trials.

Availability, Compounding, and Current Status

Retatrutide is not FDA-approved and is not legally available as a commercial prescription product in the United States or internationally. Phase 3 trials are ongoing across multiple indications (obesity, type 2 diabetes, MASLD, osteoarthritis).

Eli Lilly has not yet submitted a New Drug Application (NDA). Analyst estimates place potential FDA approval in 2027–2028, assuming Phase 3 results remain consistent with Phase 2 data.

Because retatrutide is not on the FDA shortage list and is not a commercially approved drug, compounding pharmacies cannot legally produce it for patient use in the United States under current 503A/503B rules. The peptide is available as a research compound from peptide synthesis labs, but this carries significant risk — no regulatory oversight, unknown purity, and no clinical dosing guidance validated for human use outside of supervised trials.

This is an important distinction from compounded semaglutide or tirzepatide, which were produced by 503A/503B pharmacies when the drugs were on FDA drug shortage lists.

Who Might Benefit Most?

Based on current trial data, retatrutide may offer particular advantages for:

• People who did not achieve adequate response to semaglutide or tirzepatide — the additional glucagon mechanism may produce weight loss in patients where GLP-1/GIP alone plateaued.
• Individuals with metabolic-associated fatty liver disease (MASLD/MASH) — the 82% liver fat reduction data is exceptional.
• Class II/III obesity with metabolic comorbidities — the magnitude of weight loss at 12 mg is in territory previously only achievable with bariatric surgery.
• Type 2 diabetes with obesity — the combination of glycemic control and weight loss could be disease-modifying.

What to Watch For

Several Phase 3 TRIUMPH trials are ongoing. Key results to watch include:

• TRIUMPH-1: Obesity without diabetes, 72-week primary endpoint
• TRIUMPH-2: Type 2 diabetes, glycemic and weight outcomes
• TRIUMPH-3: Cardiovascular outcomes
• Continued readouts on MASLD from the Nature Medicine Phase 2a cohort extension

The cardiovascular outcomes trial is particularly significant. Semaglutide's SELECT trial demonstrated a 20% reduction in major cardiovascular events — if retatrutide can replicate or exceed this with greater weight reduction, it could become the standard of care for cardiometabolic risk.

Conclusion

Retatrutide represents the most significant advance in obesity pharmacotherapy to date. Its triple mechanism — combining appetite suppression, insulin sensitization, and thermogenic energy expenditure — produces weight loss figures that approach surgical outcomes in some patients, along with meaningful improvements in liver disease and glycemic control.

It is not yet available, and rushing to obtain unregulated research-grade compounds carries real risks. But for those managing obesity, metabolic liver disease, or treatment-resistant type 2 diabetes, retatrutide is the drug to watch most closely over the next 24 months.

When it arrives, the GLP-1 landscape will look different.